Compare AVXL & TCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVXL | TCI |
|---|---|---|
| Founded | 2004 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.2M | 308.7M |
| IPO Year | 2013 | 1994 |
| Metric | AVXL | TCI |
|---|---|---|
| Price | $2.73 | $39.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $22.00 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 2.0K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 135.29 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $49,060,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1,971.00 |
| Revenue Growth | N/A | ★ 4.23 |
| 52 Week Low | $2.41 | $31.48 |
| 52 Week High | $13.99 | $59.65 |
| Indicator | AVXL | TCI |
|---|---|---|
| Relative Strength Index (RSI) | 48.25 | 54.59 |
| Support Level | $2.62 | $34.57 |
| Resistance Level | $3.07 | $47.25 |
| Average True Range (ATR) | 0.18 | 1.39 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 48.48 | 56.30 |
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates in two business segments: the acquisition, development, ownership and management of multifamily properties; and the acquisition, development, ownership and management of commercial properties; which are office properties. The services for its commercial segment include rental of office space and other tenant services, including parking and storage space rental. The services for its multifamily segment include rental of apartments and other tenant services, including parking and storage space rental. the company derives maximum revenue from Multifamily Segment.